奈达铂同步放化疗治疗晚期非小细胞肺癌的增敏作用的临床观察

目的 探讨奈达铂（nedaplatin，NDP）同步放化疗治疗晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）的增敏作用。方法 将68例晚期非小细胞肺癌患者随机分为对照组和治疗组，对照组给予单纯放射治疗，治疗组给予奈达铂增敏同步放化疗治疗，两组放射治疗均采用三维适形放疗，治疗完成后4周对患者的治疗效果进行评价，并观察其不良反应。结果 治疗完成4周后对患者的治疗效果评价结果显示，对照组的有效率为38.2%，疾病控制率为85.3%；治疗组的有效率为64.7%，疾病控制率为91.2%。两组比较的结果表明，与对照组相比，治疗组的有效率和疾病控制率均得到明显的改善，具有显著的差异（P<0.05）。同时，对两组患者生存率的统计结果也表明，与对照组相比，治疗组一年及两年的生存率得到了明显的提高，差异具有显著的统计学意义（P<0.05）。此外，对毒副作用的观察结果表明，同步放化疗不良反应主要表现为骨髓抑制、胃肠道反应及肾毒性等。结论 同步放化疗联合奈达铂治疗晚期非小细胞肺癌具有显著的增敏作用，其增敏作用的机制有待进一步的研究。

Observation on the effect of nedaplatin concurrent with radiotherapy and chemotherapy for locally advanced non-small cell lung cancer

Objective To investigate the sensitization effect of concurrent nedaplatin (NDP) chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Sixty-eight patients who had been diagnosed as advanced NSCLC were randomly divided into control and treatment groups. The control group received radiotherapy alone. The treatment group received NDP sensitization and concurrent radiotherapy and chemotherapy. Three groups of radiation therapy used three-dimensional conformal radiotherapy. The treatment effect of the patient was evaluated 4 weeks after the completion of the treatment and the adverse reactions were observed. Results After 4 weeks of treatment, the results of the evaluation of the patient's treatment showed that the effective rate in the control group was 38.2%, the disease control rate was 85.3%, the effective rate in the treatment group was 64.7%, and the disease control rate was 91.2%. The results of the two groups showed that compared with the control group, the treatment group's efficiency and disease control rate were significantly improved, with significant differences (P<0.05). At the same time, the statistical results of the survival rates of the two groups of patients also showed that compared with the control group, the survival rate of the treatment group was significantly improved in one year and two years, the difference was statistically significant (P<0.05). Moreover, the observation of toxic side effects showed that the main adverse reactions were myelosuppression, gastrointestinal reactions and nephrotoxicity. Conclusion The efficacy of NDP concurrent chemoradiation in the treatment of advanced NSCLC is significant, but due to the limited number of cases, the sensitization of NDP to NSCLC remains to be further studied.